Difference between revisions of "Immune effector cells toxicity management"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.") |
Warner-admin (talk | contribs) m (Text replacement - "</big>" to "") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
|- | |- | ||
|style="background-color:#F0F0F0; width:15%"|[[File:Zubiri.png|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0; width:15%"|[[File:Zubiri.png|frameless|upright=0.3|center]] | ||
| − | |style="width:35%" | | + | |style="width:35%" |Leyre Zubiri, MD, PhD<br>Massachusetts General Hospital<br>Boston, MA |
|style="background-color:#F0F0F0; width:15%"|[[File:Hadfield.jpeg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0; width:15%"|[[File:Hadfield.jpeg|frameless|upright=0.3|center]] | ||
| − | |style="width:35%" | | + | |style="width:35%" |Matthew Hadfield, DO<br>Lifespan/Brown University<br>Providence, RI<br>[https://www.linkedin.com/in/matthew-hadfield-do-0014621a/ LinkedIn] |
|- | |- | ||
|} | |} | ||
| − | + | '''The purpose of this page is to address the management of toxicity from bispecific T-cell engager and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, [[Immunotherapy_toxicity_management|available here]].''' | |
| − | * | + | *''We have moved [[How I Treat]] articles to a dedicated page.'' |
{{TOC limit|limit=4}} | {{TOC limit|limit=4}} | ||
| Line 18: | Line 18: | ||
*'''2021:''' Santomasso et al. [https://doi.org/10.1200/jco.21.01992 Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline] | *'''2021:''' Santomasso et al. [https://doi.org/10.1200/jco.21.01992 Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline] | ||
==ASTCT== | ==ASTCT== | ||
| − | *'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] | + | *'''2019:''' Lee et al. [https://doi.org/10.1016/j.bbmt.2018.12.758 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells] [https://pubmed.ncbi.nlm.nih.gov/30592986/ PubMed] |
| + | ==Consensus recommendations== | ||
| + | *'''2024:''' Crombie et al. [https://doi.org/10.1182/blood.2023022432 Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy] [https://pubmed.ncbi.nlm.nih.gov/38252906/ PubMed] | ||
| + | |||
==EBMT/JACIE/EHA== | ==EBMT/JACIE/EHA== | ||
*'''2023:''' Rejeski et al. [https://doi.org/10.1182/blood.2023020578 Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations] [https://pubmed.ncbi.nlm.nih.gov/37300386/ PubMed] | *'''2023:''' Rejeski et al. [https://doi.org/10.1182/blood.2023020578 Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations] [https://pubmed.ncbi.nlm.nih.gov/37300386/ PubMed] | ||
| Line 24: | Line 27: | ||
==SITC== | ==SITC== | ||
| − | *'''2020:''' Maus et al. [ | + | *'''2020:''' Maus et al. [https://doi.org/10.1136/jitc-2020-001511 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events] |
=REMS programs for CAR T-cells= | =REMS programs for CAR T-cells= | ||
Latest revision as of 00:28, 4 July 2024
| Page co-editor | Page co-editor | ||
|---|---|---|---|
 |
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
 |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
The purpose of this page is to address the management of toxicity from bispecific T-cell engager and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.
- We have moved How I Treat articles to a dedicated page.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2021: Santomasso et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells PubMed
Consensus recommendations
- 2024: Crombie et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy PubMed
EBMT/JACIE/EHA
- 2023: Rejeski et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations PubMed
- 2022: Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) PubMed
SITC
- 2020: Maus et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events